Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | WIZ | O95785 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30828180 | 1.00 | CRBN (0.58) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| Hydrochloric Acid SCHEMBL30828256 | 0.99 | CRBN (0.57) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| Hydrochloric Acid SCHEMBL27194531 | 0.99 | CRBN (0.57) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL30828152 | 0.87 | CRBN (0.52) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL27194328 | 0.87 | CRBN (0.52) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL30889713 | 0.86 | CRBN (0.57) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL24207552 | 0.86 | CRBN (0.61) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL31586460 | 0.86 | CRBN (0.61) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL31586364 | 0.85 | CRBN (0.55) | CRBNCSNK1A1ESR1WIZIKZF2 | |
| SCHEMBL29158021 | 0.84 | CRBN (0.69) | CRBNCSNK1A1WIZIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11957759-B1 | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | CRBN 298/4885CSNK1A1 264/4885ESR1 4756/4885 |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | CRBN 968/4885CSNK1A1 3361/4885ESR1 4325/4885 |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | BRAF, ARAF, RAF1 | CRBN 283/4885CSNK1A1 281/4885ESR1 4764/4885 |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | CRBN 968/4885CSNK1A1 3361/4885ESR1 4325/4885 |
| US-11957759-B1 | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | CRBN 277/4885CSNK1A1 273/4885ESR1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.